Hamill John P.
SEC CIK 1716213 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | CFO, SrVP, Prin. Fin, Acctg. Off | 43.5K | $19.6K | — | 10 | 2023-01-30 | 2026-03-12 |
Most active insiders at APRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Duey Marc | Dir | $25.1K | — |
| 2 | Gilad Oren | Pres, CEO, Dir | $25.0K | — |
| 3 | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | $10.9K | — |
| 4 | Pamukcu Rifat | Dir | — | — |
| 5 | Gruia Gabriela | Dir | — | — |
| 6 | Seizinger Bernd R. | Dir | — | — |
| 7 | Grissinger Michael | Dir | — | — |
| 8 | Peters Richard | Dir | — | — |
| 9 | BIZZARI JEAN-PIERRE | Dir | — | — |
| 10 | HENNEMAN JOHN B III | Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-16 | 2026-03-12 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +10.1K | 43.5K | +30% | $0 |
| D | 2026-02-02 | 2026-01-30 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $0.89 | +5,700 | 33.4K | +21% | +$5,073 |
| D | 2025-12-11 | 2025-12-10 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $1.17 | +5,000 | 27.7K | +22% | +$5,850 |
| D | 2025-03-31 | 2025-03-27 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +3,365 | 22.7K | +17% | $0 |
| 2024-10-16 | 2024-10-11 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $2.46 | +50 | 19.4K | +0.3% | +$123 | |
| 2024-10-15 | 2024-10-10 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $2.61 | +450 | 19.3K | +2% | +$1,174 | |
| D | 2024-03-28 | 2024-03-28 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $0.00 | +3,365 | 18.9K | +22% | $0 |
| D | 2024-03-14 | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | P - Purchase | $7.29 | +1,010 | 15.5K | +7% | +$7,363 |
| 2023-02-27 | 2023-02-27 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin Fin, Acct Ofcr | A - Grant | $5.25 | +1,000 | 14.5K | +7% | +$5,250 | |
| D | 2023-01-30 | 2023-01-30 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | CFO, SrVP, Prin. Fin, Acctg. Off | A - Grant | $0.00 | +269.9K | 269.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations